Intraputamenal infusion of GDNF in aged rhesus monkeys: Distribution and dopaminergic effects
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Site‐specific delivery of trophic factors in the brain may be important for achieving therapeutic efficacy without unwanted side effects. This study evaluated the site‐specific infusion of glial cell line–derived neurotrophic factor (GDNF) into the right putamen of aged rhesus monkeys. After 4 weeks of continuous infusion at a rate of 22.5 μg/day, GDNF had diffused up to 11 mm from the catheter openings in the putamen into the rostral putamen, internal capsule, external capsule, caudate nucleus, and globus pallidus. Anisotropic flow along the external capsule tracts carried GDNF into the anterior amygdaloid area. Backflow of GDNF along the catheter track from the frontal cortex infiltrated juxtaposed corpus callosal and cortical tissue. GDNF was carried by retrograde transport to dopamine neurons in the ipsilateral substantia nigra, stimulating an 18% increase in the number of tyrosine hydroxylase (TH)–positive dopamine neurons and a 28% increase in dopamine neuron perikaryal size. Also, TH‐positive fiber density was increased in the ipsilateral globus pallidus, caudate nucleus, and putamen. Anatomic effects from GDNF stimulation of the dopaminergic system were restricted to the ipsilateral hemisphere. Retrograde GDNF labeling was also present in a few TH‐positive neurons in the locus coeruleus and a large cluster of TH‐negative neurons in the ventral anterior thalamus. Anterograde transport of GDNF was evident in axons in the pyramidal tract from the cerebral peduncle to the caudal spinal cord. Tissue injury from the intraparenchymal catheter and continuous infusion was confined primarily to a narrow zone surrounding the track and was mild to moderate in severity. J. Comp. Neurol. 461:250–261, 2003. © 2003 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
West, M. J., Slomianka, L., & Gundersen, H. J. G. (1991) · The Anatomical Record · doi:10.1002/ar.1092310411 · Cited by 2,994
Functional recovery in parkinsonian monkeys treated with GDNF
Gash, D. M., Zhang, Z., Ovadia, A., Cass, W. A., Yi, A., Simmerman, L., Russell, D., Martin, D., Lapchak, P. A., Collins, F., et al. (1996) · Nature · doi:10.1038/380252a0 · Cited by 955 · cited 1×
“…factors; basal ganglia; substantia nigra; dopamine neurons Because of its potent protective and restorative effects on midbrain dopamine neurons, glial cell line–derived neurotrophic factor (GDNF) holds great promise for treating Parkinson’s disease (Gash et al., 1996, 1998; Kordower et al., 2000).”
BackgroundSelf-citationNew stereological methods for counting neurons
West, M. J. (1993) · Neurobiology of Aging · doi:10.1016/0197-4580(93)90112-o · Cited by 940 · cited 1×
“…of TH-positive neurons The number and perikaryal size of TH-positive neurons in the substantia nigra pars compacta (SNC) were estimated by using an optical fractionator method for unbiased stereologic cell counting (Bioquant Image Analysis System; West et al., 1991; West 1993; Harding al., 1994).”
Method
Cited by
The blood-brain barrier: Bottleneck in brain drug development
Pardridge, W. M. (2005) · NeuroRX · doi:10.1602/neurorx.2.1.3 · Cited by 2,798
“The direction of fluid flow, principally via white matter tracts,(19) can be traced with immunocytochemistry using an antibody to GFAP, which shows an astrogliotic reaction in the path of fluid flow.(20) The hole in the brain left by the catheter is noted by the asterisk.”
BackgroundPardridge, W. M. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2006.10.013 · Cited by 1,191
‘Rejuvenation’ protects neurons in mouse models of Parkinson’s disease
Chan, C. S., Guzman, J. N., Ilijic, E., Mercer, J. N., Rick, C., Tkatch, T., Meredith, G. E., & Surmeier, D. J. (2007) · Nature · doi:10.1038/nature05865 · Cited by 904
GDNF, NGF and BDNF as Therapeutic Options for Neurodegeneration
Allen, S. J., Watson, J. J., Shoemark, D. K., Barua, N. U., & Patel, N. K. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.01.004 · Cited by 820
“A number of studies have investigated the effects of continuous intraputamenal delivery of GDNF at doses ranging from 7.5 to 22.5 μg/day in both intact aged and MPTP-lesioned non-human primates (Maswood et al., 2001; Grondin et al., 2002; Ai et al., 2003; Grondin et al., 2003).”
BackgroundInfluentialSlevin, J. T., Gerhardt, G. A., Smith, C. D., Gash, D. M., Kryscio, R., & Young, B. (2005) · Journal of Neurosurgery · doi:10.3171/jns.2005.102.2.0216 · Cited by 475
Self-citationPardridge, W. M. (2007) · Pharmaceutical Research · doi:10.1007/s11095-007-9324-2 · Cited by 447
The aging brain: morphomolecular senescence of cortical circuits
Hof, P. R., & Morrison, J. H. (2004) · Trends in Neurosciences · doi:10.1016/j.tins.2004.07.013 · Cited by 411
Maswood, N., Young, J., Tilmont, E., Zhang, Z., Gash, D. M., Gerhardt, G. A., Grondin, R., Roth, G. S., Mattison, J., Lane, M. A., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405831102 · Cited by 385
Self-citationThe role of Nurr1 in the development of dopaminergic neurons and Parkinson's disease
Jankovic, J., Chen, S., & Le, W. D. (2005) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2005.09.001 · Cited by 325
Localized striatal delivery of GDNF as a treatment for Parkinson disease
Kirik, D., Georgievska, B., & Björklund, A. (2004) · Nature Neuroscience · doi:10.1038/nn1175 · Cited by 290
Point source concentration of GDNF may explain failure of phase II clinical trial
SALVATORE, M., AI, Y., FISCHER, B., ZHANG, A., GRONDIN, R., ZHANG, Z., GERHARDT, G., & GASH, D. (2006) · Experimental Neurology · doi:10.1016/j.expneurol.2006.07.015 · Cited by 260
Self-citationMolecular Trojan horses for blood–brain barrier drug delivery
PARDRIDGE, W. (2006) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2006.06.001 · Cited by 260
A Historical Review of Brain Drug Delivery
Pardridge, W. M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061283 · Cited by 219
Six-month partial suppression of Huntingtin is well tolerated in the adult rhesus striatum
Grondin, R., Kaytor, M. D., Ai, Y., Nelson, P. T., Thakker, D. R., Heisel, J., Weatherspoon, M. R., Blum, J. L., Burright, E. N., Zhang, Z., et al. (2012) · Brain · doi:10.1093/brain/awr333 · Cited by 153
Self-citationCHEN, Y., AI, Y., SLEVIN, J., MALEY, B., & GASH, D. (2005) · Experimental Neurology · doi:10.1016/j.expneurol.2005.07.010 · Cited by 126
Self-citationHerzog, C. D., Dass, B., Gasmi, M., Bakay, R., Stansell, J. E., Tuszynski, M., Bankiewicz, K., Chen, E.-Y., Chu, Y., Bishop, K., et al. (2008) · Molecular Therapy · doi:10.1038/mt.2008.170 · Cited by 72
Trophic factors therapy in Parkinson's disease
Ramaswamy, S., Soderstrom, K. E., & Kordower, J. H. (2009) · Progress in Brain Research · doi:10.1016/s0079-6123(09)17514-3 · Cited by 72
Promising therapeutic agents for the treatment of Parkinson’s disease
Majláth, Z., Török, N., Toldi, J., & Vécsei, L. (2016) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2016.1164687 · Cited by 7
Metadata
- Authors
- Ai, Y., Markesbery, W., Zhang, Z., Grondin, R., Elseberry, D., Gerhardt, G. A., & Gash, D. M.
- Venue
- Journal of Comparative Neurology
- Publisher
- Wiley
- Published
- 2003-04-25
- Volume
- 461
- Issue
- 2
- Pages
- 250-261
- ISSN
- 0021-9967 (ISSN-L)
- 1096-9861
- OpenAlex
- W2105696266
- Cited by
- 149
- References
- 3
- FWCI
- 4.00
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.